glp-1 drugs shortage = Over GLP-1 Drugs: FDA Removes Lilly's

Description

Pfizers dose-optimization studies of once-daily formulations of danuglipron ( NCT06567327 and NCT06568731 ) met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in Phase 3 testing, based on earlier studies of twice-daily danuglipron

Discover Ozempic alternatives for type 2 diabetes and weight loss, including GLP-1s and oral medications

This is where wellness starts to collide with pharma

Discover smell sensitivity, and what to do if GLP1s like Ozempic, Wegovy, or Mounjaro have altered your sense of smell.

Summary GLP-1 RAs offer a multifaceted therapeutic strategy in PD, targeting both central neurodegenerative processes and peripheral metabolic dysfunction